Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38875108

FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Clin Cancer Res
Publication date
2024 Aug 15
First author
Barbato MI

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Barbato MI
      type
      Author
    2. name
      Bradford D
      type
      Author
    3. name
      Ren Y
      type
      Author
    4. name
      Aungst SL
      type
      Author
    5. name
      Miller CP
      type
      Author
    6. name
      Pan L
      type
      Author
    7. name
      Zirkelbach JF
      type
      Author
    8. name
      Li Y
      type
      Author
    9. name
      Bi Y
      type
      Author
    10. name
      Fan J
      type
      Author
    11. name
      Grimstein M
      type
      Author
    12. name
      Dorff SE
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Barbato MI
      type
      Author
    2. name
      Bradford D
      type
      Author
    3. name
      Ren Y
      type
      Author
    4. name
      Aungst SL
      type
      Author
    5. name
      Miller CP
      type
      Author
    6. name
      Pan L
      type
      Author
    7. name
      Zirkelbach JF
      type
      Author
    8. name
      Li Y
      type
      Author
    9. name
      Bi Y
      type
      Author
    10. name
      Fan J
      type
      Author
    11. name
      Grimstein M
      type
      Author
    12. name
      Dorff SE
      type
      Author
    bibliography ids
    1. nci-bib-f0f21147cfbe53547381e817
    book metadata
    content sha256
    4d440fa2ec1fd97b7a210f72990179e8fa5d4127e1334afb0ecf110c1993df81
    document type
    citation
    dois
    1. 10.1158/1078-0432.CCR-24-0949
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:38875108
    immutable id
    pubmed:38875108@4d440fa2ec1fd97b7a210f72990179e8fa5d4127e1334afb0ecf110c1993df81
    journal
    abbreviation
    Clin Cancer Res
    issn electronic
    1557-3265
    issn print
    1078-0432
    issue
    16
    name
    Clinical cancer research : an official journal of the American Association for Cancer Research
    nlm unique id
    9502500
    pages
    3364-3370
    volume
    30
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      38875108
      provenance
      batch id
      3e43afde6f26fc8df6da
      provider
      NCBI PubMed ESummary
      record sha256
      9b7ead80da1ba5b5050e7b7143bfba9a20fe0fa3ec61e8a2e72118715db1acbf
      response sha256
      fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
      retrieved at
      2026-09-09T23:48:21.145285+00:00
      publication date
      display
      2024 Aug 15
      precision
      day
      year
      2024
      publication types
      1. Clinical Trial, Phase I
      2. Clinical Trial, Phase II
      3. Journal Article
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/38875108/
      title
      FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.

      Preserved source evidence · Not medical advice